Univercells Technologies, a global provider of next-gen bioprocess technologies, has been launched as a subsidiary of Univercells, under which it will focus on the commercialization of the product portfolio and explore new technology developments to expand its position in the cell and gene therapy market.   

According to Mathias Garny, General Manager of Univercells Technologies, “With the scale – X bioreactor portfolio and the NevoLine biomanufacturing platform, designed and commercially validated by Univercells, the company experiences a turning point. The commercialization of these cutting-edge technologies under a dedicated brand will boost the expansion of our market reach to support advances in cell and gene therapy manufacturing,”
 
As hundreds of cell and gene therapies enter clinical trials, commercial progress remains hindered by manufacturing capacity and reproducibility constraints during process scale-up. Univercells Technologies scale-X bioreactor portfolio and the NevoLine platform for cell and gene therapy manufacture aims to provide effective and validated solution for scalable therapy manufacturing. The technology portfolio is also suited to allow mass production of large quantities of human and veterinary vaccines.